Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) just unveiled an announcement.
MindBio Therapeutics has successfully completed dosing in its landmark Phase 2B clinical trial for its lead candidate drug MB22001, a take-home microdose formulation of LSD designed for treating Major Depressive Disorder. This trial, which is a world-first in receiving regulatory approval for take-home psychedelic medicine, positions MindBio as a leader in the development of advanced take-home psychedelic treatments, potentially paving the way for commercialization and Phase 3 trials, and offering a promising alternative to traditional antidepressants.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, focused on developing novel psychedelic-based medicines for mental health disorders. The company is pioneering the use of regulated, take-home microdoses of psychedelic medicines in clinical trials to provide safe, effective, and scalable treatments for conditions such as depression and anxiety, aiming to improve global mental health outcomes through innovative, evidence-based treatment that is accessible and affordable.
Average Trading Volume: 144,500
Technical Sentiment Signal: Sell
Current Market Cap: C$2.73M
For a thorough assessment of MBIO stock, go to TipRanks’ Stock Analysis page.